Update on therapeutic vascularization strategies

Regenerative Medicine

Volumn 4, Issue 1, 2009, Pages 65-80

  Phelps, Edward A ^a,b   Garcia, Andres J ^a,b  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Angiogenesis; Angiogenic therapy; Growth factor; Therapeutic vascularization; VEGF

Indexed keywords

ALPHA4 INTEGRIN ANTIBODY; ANGIOGENIC FACTOR; FIBROBLAST GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR; MACROGOL; SCATTER FACTOR; SCLEROPROTEIN; SODIUM NITRITE; UNCLASSIFIED DRUG; VASCULOTROPIN; BIOMATERIAL; SIGNAL PEPTIDE;

ANGIOGENESIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BIOLOGICAL ACTIVITY; BRANCHING MORPHOGENESIS; CELL DIFFERENTIATION; CELL EXPANSION; CELL MIGRATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG COATING; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG OVERDOSE; EXTRACELLULAR MATRIX; HEART INFARCTION; HUMAN; ISCHEMIA; ISCHEMIC HEART DISEASE; LEG ISCHEMIA; LOW DRUG DOSE; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; STEM CELL MOBILIZATION; TISSUE ENGINEERING; TISSUE PERFUSION; ANIMAL; BIOLOGICAL MODEL; BIOLOGICAL THERAPY; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY);

ANGIOGENESIS INDUCING AGENTS; ANIMALS; BIOCOMPATIBLE MATERIALS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ISCHEMIA; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; TISSUE ENGINEERING; TISSUE THERAPY;

EID: 58949098920     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460751.4.1.65     Document Type: Review

References (134)

1. Lu C, Hansen E, Sapozhnikova A, Hu D, Miclau T, Marcucio RS: Effect of age on vascularization during fracture repair. J. Orthop. Res. 26(10), 1386-1389 (2008).
2. Takeshita S, Zheng LP, Brogi E et al.: Therapeutic angiogenesis. A single intraarterial bolus of VEGF augments revascularization in a rabbit ischemic hind limb model. J. Clin. Invest. 93, 662-670 (1994).
3. van Weel V, van Tongeren RB, van Hinsberg VW, van Bockel JH, Quax PH: Vascular growth in ischemic limbs: a review of mechanisms and possible therapeutic stimulation. Ann. Vasc. Surg. 22, 582-597 (2008).
4. Simons M, Ware JA: Therapeutic angiogenesis in cardiovascular disease. Nat. Rev. Drug Discov. 2, 863-871 (2003).
5. Renault MA, Losordo DW: Therapeutic myocardial angiogenesis. Microvasc. Res. 74, 159-171 (2007).
6. Tongers J, Roncalli JG, Losordo DW: Therapeutic angiogenesis for critical limb ischemia: microvascular therapies coming of age. Circulation 118, 9-16 (2008).
7. Jacobs J: Combating cardiovascular disease with angiogenic therapy. Drug Discov. Today 12, 1040-1045 (2007).
8. Tse HF, Lau CP: Therapeutic angiogenesis with bone marrow-derived stem cells. J. Cardiovasc. Pharmacol. Ther. 12, 89-97 (2007).
9. Kuhlmann MT, Klocke R, Nikol S: Therapeutic angiogenesis for peripheral artery disease: cytokine therapy. VASA 36, 253-260 (2007).
10. Lachmann N, Nikol S: Therapeutic angiogenesis for peripheral artery disease: stem cell therapy. VASA 36, 241-251 (2007).
11. Simons M: Angiogenesis: where do we stand now? Circulation 111, 1556-1566 (2005).
12. Carmeliet P: Angiogenesis in health and disease. Nat. Med. 9, 653-660 (2003).
13. Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6, 389-395 (2000).
14. Adams RH, Alitalo K: Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol. 8, 464-478 (2007).
15. Davies N, Dobner S, Bezuidenhout D et al.: The dosage dependence of VEGF stimulation on scaffold neovascularisation. Biomaterials 29, 3531-3538 (2008).
16. Djonov V, Baum O, Burri PH: Vascular remodeling by intussusceptive angiogenesis. Cell Tissue. Res. 314, 107-117 (2003).
17. le Noble F, Klein C, Tintu A, Pries A, Buschmann I: Neural guidance molecules, tip cells and mechanical factors in vascular development. Cardiovasc. Res. 78, 232-241 (2008).
18. Wilson BD, Ii M, K Park W et al.: Netrins promote developmental and therapeutic angiogenesis. Science 313, 640-644 (2006).
19. Luttun A, Tjwa M, Carmeliet P: Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann. NY Acad. Sci. 979, 80-93 (2002).
20. Khurana R, Simons M: Insights from angiogenesis trials using FGF for advanced arteriosclerotic disease. Trends Cardiovasc. Med. 13, 116-122 (2003).
21. Hao X, Silva EA, Mansson-Broberg A et al.: Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc. Res. 75, 178-185 (2007).
22. Pipp F, Boehm S, W Cai J et al.: Elevated fluid shear stress enhances postocclusive collateral artery growth and gene expression in the pig hind limb. Arterioscler. Thromb. Vasc. Biol. 24, 1664-1668 (2004).
23. Cai W, Schaper W: Mechanisms of arteriogenesis. Acta. Biochim. Biophys. Sin. (Shanghai) 40, 681-692 (2008).
24. Murray CD: The physiological principle of minimum work: I. The vascular system and the cost of blood volume. Proc. Natl Acad. Sci. USA 12, 207-214 (1926).
25. Murray CD: The Physiological principle of minimum work: II. Oxygen exchange in capillaries. Proc. Natl Acad. Sci. USA 12, 299-304 (1926).
26. Purhonen S, Palm J, Rossi D et al.: Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc. Natl Acad. Sci. USA 105, 6620-6625 (2008).
27. Kocher A, Schuster MD, Szabolcs MJ et al.: Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med. 7, 430-436 (2001).
28. Stamm C, Westphal B, Kleine HD et al.: Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 361, 45-46 (2003).
29. Beeres SL, Bax JJ, Dibbets-Schneider P et al.: Intramyocardial injection of autologous bone marrow mononuclear cells in patients with chronic myocardial infarction and severe left ventricular dysfunction. Am. J. Cardiol. 100, 1094-1098 (2007).
30. Asahara T, Kawamoto A: Endothelial progenitor cells for postnatal vasculogenesis. Am. J. Physiol., Cell Physiol. 287, C572-C579 (2004).
31. Carmeliet P: VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat. Med. 6, 1102-1103 (2000).
32. Sun Q, Chen RR, Shen Y, Mooney DJ, Rajagopalan S, Grossman PM: Sustained VEGF delivery enhances angiogenesis and perfusion in ischemic hind limb. Pharm. Res. 22, 1110-1116 (2005).
33. Simons M, Bonow RO, N Chronos A et al.: Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation 102, E73-E86 (2000).
34. Ennett AB, Kaigler D, Mooney DJ: Temporally regulated delivery of VEGF in vitro and in vitro. J. Biomed. Mater. Res. A 79, 176-184 (2006).
35. Dietrich F, Lelkes PI: Fine-tuning of a three-dimensional microcarrier-based angiogenesis assay for the analysis of endothelial-mesenchymal cell co-cultures in fibrin and collagen gels. Angiogenesis 9, 111-125 (2006).
36. Nehls V, Drenckhahn D: A novel, microcarrier-based in vitro assay for rapid and reliable quantification of three-dimensional cell migration and angiogenesis. Microvasc. Res. 50, 311-322 (1995).
37. Chen RR, Silva EA, W Yuen W et al.: Integrated approach to designing growth factor delivery systems. FASEB. J. 21, 3896-3903 (2007).
38. Gerhardt H, Golding M, Fruttiger M et al.: VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell. Biol. 161, 1163-1177 (2003).
39. Fleury ME, Boardman KC, Swartz MA: Autologous morphogen gradients by subtle interstitial flow and matrix interactions. Biophys. J. 91, 113-121 (2006).
40. Helm CL, Fleury ME, Zisch AH, Boschetti F, Swartz MA: Synergy between interstitial flow and VEGF directs capillary morphogenesis in vitro through a gradient amplification mechanism. Proc. Natl Acad. Sci. USA 102, 15779-15784 (2005).
41. Semino CE, Kamm RD, Lauffenburger DA: Autocrine EGF receptor activation mediates endothelial cell migration and vascular morphogenesis induced by VEGF under interstitial flow. Exp. Cell. Res. 312, 289-298 (2006).
42. Luttun A, Tjwa M, Moons L et al.: Revascularization of ischemic tissues by PlGF treatment and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 8, 831-840 (2002).
43. Carmeliet P, Moons L, Luttun A et al.: Synergism between VEGF and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7, 575-583 (2001).
44. van Royen N, Piek JJ, Buschmann I, Hoefer I, Voskuil M, Schaper W: Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc. Res. 49, 543-553 (2001).
45. Silva EA, Mooney DJ: Spatiotemporal control of VEGF delivery from injectable hydrogels enhances angiogenesis. J. Thromb. Haemost. 5, 590-598 (2007).
46. Hopkins SP, Bulgrin JP, Sims RL, Bowman B, Donovan DL, Schmidt SP: Controlled delivery of VEGF promotes neovascularization and maintains limb function in a rabbit model of ischemia. J. Vasc. Surg. 27, 886-894 (1998).
47. Jain RK: Molecular regulation of vessel maturation. Nat. Med. 9, 685-693 (2003).
48. Dellian M, Witwer BP, Salehi HA, Yuan F, Jain RK: Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic FGF, VEGF/vascular permeability factor and host microenvironment. Am. J. Pathol. 149, 59-71 (1996).
49. Chen RR, Silva EA, Yuen WW, Mooney DJ: Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm. Res. 24, 258-264 (2007).
50. Richardson TP, Peters MC, Ennett AB, Mooney DJ: Polymeric system for dual growth factor delivery. Nat. Biotechnol. 19, 1029-1034 (2001).
51. Marui A, Kanematsu A, Yamahara K et al.: Simultaneous application of basic FGF and hepatocyte growth factor to enhance the blood vessels formation. J. Vasc. Surg. 41, 82-90 (2005).
52. Shyu KG, Chang H, Isner JM: Synergistic effect of angiopoietin-1 and VEGF on neoangiogenesis in hypercholesterolemic rabbit model with acute hindlimb ischemia. Life Sci. 73, 563-579 (2003).
53. Zohlnhofer D, Ott I, Mehilli J et al.: Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 295, 1003-1010 (2006).
54. Horowitz A, Simons M: Branching morphogenesis. Circ. Res. 103, 784-795 (2008).
55. Vincent KA, Shyu KG, Luo Y et al.: Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1α/ VP16 hybrid transcription factor. Circulation 102, 2255-2261 (2000).
56. Shyu KG, Wang MT, Wang BW et al.: Intramyocardial injection of naked DNA encoding HIF-1α/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc. Res. 54, 576-583 (2002).
57. Rajagopalan S, Olin J, Deitcher S et al.: Use of a constitutively active hypoxia-inducible factor-1α transgene as a therapeutic strategy in no-option critical limb ischemia patients: Phase I dose-escalation experience. Circulation 115, 1234-1243 (2007).
58. Elson DA, Thurston G, Huang LE et al.: Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1α. Genes Dev. 15, 2520-2532 (2001).
59. Liu L, Marti GP, Wei X et al.: Age-dependent impairment of HIF-1α expression in diabetic mice: Correction with electroporation-facilitated gene therapy increases wound healing, angiogenesis and circulating angiogenic cells. J. Cell Physiol. 217(2), 319-327 (2008).
60. Wang R, Zhang X, Zhang J, Xiu R: Gene transfer of VEGF plasmid/liposome complexes in glioma cells in vitro: the implication for the treatment of cerebral ischemic diseases. Clin. Hemorheol. Microcirc. 23, 303-306 (2000).
61. Xie D, Li Y, Reed EA, Odronic SI, Kontos CD, Annex BH: An engineered VEGF-activating transcription factor induces therapeutic angiogenesis in ApoE knockout mice with hindlimb ischemia. J. Vasc. Surg. 44, 166-175 (2006).
62. Dai Q, Huang J, Klitzman B et al.: Engineered zinc finger-activating VEGF transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia. Circulation 110, 2467-2475 (2004).
63. Fuchs S, Baffour R, Zhou YF et al.: Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J. Am. Coll. Cardiol. 37, 1726-1732 (2001).
64. Gavira JJ, Herreros J, Perez A et al.: Autologous skeletal myoblast transplantation in patients with nonacute myocardial infarction: 1-year follow-up. J. Thorac. Cardiovasc. Surg. 131, 799-804 (2006).
65. Menasche P, Alfieri O, Janssens S et al.: The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 117, 1189-1200 (2008).
66. Menasche P, Hagege AA, Vilquin JT et al.: Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J. Am. Coll. Cardiol. 41, 1078-1083 (2003).
67. Kalka C, Masuda H, Takahashi T et al.: Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl Acad. Sci. USA 97, 3422-3427 (2000).
68. Tateishi-Yuyama E, Matsubara H, Murohara T et al.: Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 360, 427-435 (2002).
69. Jujo K, Ii M, Losordo DW: Endothelial progenitor cells in neovascularization of infarcted myocardium. J. Mol. Cell. Cardiol. 45, 530-544 (2008).
70. Kawamoto A, Asahara T, Losordo DW: Transplantation of endothelial progenitor cells for therapeutic neovascularization. Cardiovasc. Radiat. Med. 3, 221-225 (2002).
71. Wu Y, Chen L, Scott PG, Tredget EE: Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 25, 2648-2659 (2007).
72. Matsumoto T, Kuroda R, Mifune Y et al.: Circulating endothelial/ skeletal progenitor cells for bone regeneration and healing. Bone (2008).
73. Asahara T, Murohara T, Sullivan A et al.: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967 (1997).
74. Van't Hof W, Mal N, Huang Y et al.: Direct delivery of syngeneic and allogeneic large-scale expanded multipotent adult progenitor cells improves cardiac function after myocardial infarct. Cytotherapy 9, 477-487 (2007).
75. Zampetaki A, Kirton JP, Xu Q: Vascular repair by endothelial progenitor cells. Cardiovasc. Res. 78, 413-421 (2008).
76. Penn MS, Khalil MK: Exploitation of stem cell homing for gene delivery. Expert Opin. Biol. Ther. 8, 17-30 (2008).
77. Korbling M, Estrov Z: Adult stem cells for tissue repair: a new therapeutic concept? N. Engl. J. Med. 349, 570-582 (2003).
78. Mathur A, Martin JF: Stem cells and repair of the heart. Lancet 364, 183-192 (2004).
79. Wang Y, Tagil K, Ripa RS et al.: Effect of mobilization of bone marrow stem cells by granulocyte colony stimulating factor on clinical symptoms, left ventricular perfusion and function in patients with severe chronic ischemic heart disease. Int. J. Cardiol. 100, 477-483 (2005).
80. Engelmann MG, Theiss HD, Hennig-Theiss C et al.: Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. J. Am. Coll. Cardiol. 48, 1712-1721 (2006).
81. Ripa RS, Wang Y, Jorgensen E, Johnsen HE, Hesse B, Kastrup J: Intramyocardial injection of VEGF-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur. Heart J. 27, 1785-1792 (2006).
82. Qin G, Ii M, Silver M et al.: Functional disruption of α4 integrin mobilizes bone marrow-derived endothelial progenitors and augments ischemic neovascularization. J. Exp. Med. 203, 153-163 (2006).
83. Prosper F, Stroncek D, McCarthy JB, Verfaillie CM: Mobilization and homing of peripheral blood progenitors is related to reversible downregulation of α4 β1 integrin expression and function. J. Clin. Invest. 101, 2456-2467 (1998).
84. + hematopoietic stem cells following mobilization by cyclophosphamide/granulocyte colony-stimulating factor. Exp. Hematol. 30, 176-185 (2002).
85. Kwon SM, Eguchi M, Wada M et al.: Specific Jagged-1 signal from bone marrow microenvironment is required for endothelial progenitor cell development for neovascularization. Circulation 118, 157-165 (2008).
86. Kawamoto A, Asahara T: Role of progenitor endothelial cells in cardiovascular disease and upcoming therapies. Catheter. Cardiovasc. Interv. 70, 477-484 (2007).
87. Askari A, Unzek S, Goldman CK et al.: Cellular, but not direct, adenoviral delivery of VEGF results in improved left ventricular function and neovascularization in dilated ischemic cardiomyopathy. J. Am. Coll. Cardiol. 43, 1908-1914 (2004).
88. Bian J, Kiedrowski M, Mal N, Forudi F, Penn MS: Engineered cell therapy for sustained local myocardial delivery of nonsecreted proteins. Cell Transplant. 15, 67-74 (2006).
89. Penn MS: Cell-based gene therapy for the prevention and treatment of cardiac dysfunction. Nat. Clin. Prac. Cardiovasc. Med. 4(Suppl. 1), S83-S88 (2007).
90. Jabbarzadeh E, Starnes T, Khan YM et al.: Induction of angiogenesis in tissue-engineered scaffolds designed for bone repair: a combined gene therapy - cell transplantation approach. Proc. Natl Acad. Sci. USA 105, 11099-11104 (2008).
91. Koike N, Fukumura D, Gralla O, Au P, Schechner JS, Jain RK: Tissue engineering: creation of long-lasting blood vessels. Nature 428, 138-139 (2004).
92. Kobayashi H, Shimizu T, Yamato M et al.: Fibroblast sheets co-cultured with endothelial progenitor cells improve cardiac function of infarcted hearts. J. Artif. Organs 11, 141-147 (2008).
93. Levenberg S, Rouwkema J, Macdonald M et al.: Engineering vascularized skeletal muscle tissue. Nat. Biotechnol. 23, 879-884 (2005).
94. Rizzi SC, Ehrbar M, Halstenberg S et al.: Recombinant protein-co-PEG networks as cell-adhesive and proteolytically degradable hydrogel matrixes. Part II: biofunctional characteristics. Biomacromolecules 7, 3019-3029 (2006).
95. Ehrbar M, Zeisberger SM, Raeber GP, Hubbell JA, Schnell C, Zisch AH: The role of actively released fibrin-conjugated VEGF for VEGF receptor 2 gene activation and the enhancement of angiogenesis. Biomaterials 29, 1720-1729 (2008).
96. Dye J, Lawrence L, Linge C, Leach L, Firth J, Clark P: Distinct patterns of microvascular endothelial cell morphology are determined by extracellular matrix composition. Endothelium 11, 151-167 (2004).
97. Stupack DG, Cheresh DA: Integrins and angiogenesis. Curr. Top. Dev. Biol. 64, 207-238 (2004).
98. Serini G, Napione L, Arese M, Bussolino F: Besides adhesion: new perspectives of integrin functions in angiogenesis. Cardiovasc. Res. 78, 213-222 (2008).
99. Clark RA: Synergistic signaling from extracellular matrix-growth factor complexes. J. Invest. Dermatol. 128, 1354-1355 (2008).
100. Ehrbar M, Djonov VG, Schnell C et al.: Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ. Res. 94, 1124-1132 (2004).
101. Zisch AH, Lutolf MP, Ehrbar M et al.: Cell-demanded release of VEGF from synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth. FASEB J. 17, 2260-2262 (2003).
102. Zisch AH, Lutolf MP, Hubbell JA: Biopolymeric delivery matrices for angiogenic growth factors. Cardiovasc. Pathol. 12, 295-310 (2003).
103. Gobin AS, West JL: Effects of epidermal growth factor on fibroblast migration through biomimetic hydrogels. Biotechnol. Prog. 19, 1781-1785 (2003).
104. Moon JJ, Lee SH, West JL: Synthetic biomimetic hydrogels incorporated with ephrin-A1 for therapeutic angiogenesis. Biomacromolecules 8, 42-49 (2007).
105. Hahn MS, Taite LJ, Moon JJ, Rowland MC, Ruffino KA, West JL: Photolithographic patterning of polyethylene glycol hydrogels. Biomaterials 27, 2519-2524 (2006).
106. Polizzotti BD, Fairbanks BD, Anseth KS: Three-dimensional biochemical patterning of click-based composite hydrogels via thiolene photopolymerization. Biomacromolecules 9, 1084-1087 (2008).
107. Lee SH, Moon JJ, West JL: Three-dimensional micropatterning of bioactive hydrogels via two-photon laser scanning photolithography for guided 3D cell migration. Biomaterials 29, 2962-2968 (2008).
108. Dike LE, Chen CS, Mrksich M, Tien J, Whitesides GM, Ingber DE: Geometric control of switching between growth, apoptosis and differentiation during angiogenesis using micropatterned substrates. In vitro Cell Dev. Biol. Anim. 35, 441-448 (1999).
109. Mancuso MR, Davis R, Norberg SM et al.: Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116, 2610-2621 (2006).
110. Kamba T, Tam BY, Hashizume H et al.: VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol. 290, H560-H576 (2006).
111. Fournier AE, Strittmatter SM: Regenerating nerves follow the road more traveled. Nat. Neurosci. 5, 821-822 (2002).
112. Baffert F, Le T, Sennino B et al.: Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am. J. Physiol. Heart Circ. Physiol. 290, H547-H559 (2006).
113. Vracko R, Benditt EP: Basal lamina: the scaffold for orderly cell replacement. Observations on regeneration of injured skeletal muscle fibers and capillaries. J. Cell Biol. 55, 406-419 (1972).
114. Murohara T, Asahara T, Silver M et al.: Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J. Clin. Invest. 101, 2567-2578 (1998).
115. Benest AV, Stone OA, Miller WH et al.: Arteriolar genesis and angiogenesis induced by endothelial nitric oxide synthase overexpression results in a mature vasculature. Arterioscler. Thromb. Vasc. Biol. 28, 1462-1468 (2008).
116. Yu J, deMuinck ED, Zhuang Z et al.: Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment and blood flow reserve. Proc. Natl Acad. Sci. USA 102, 10999-11004 (2005).
117. Kumar D, Branch BG, Pattillo CB et al.: Chronic sodium nitrite therapy augments ischemia-induced angiogenesis and arteriogenesis. Proc. Natl Acad. Sci. USA 105, 7540-7545 (2008).
118. Carmeliet P, Baes M: Metabolism and therapeutic angiogenesis. N. Engl. J. Med. 358, 2511-2512 (2008).
119. Arany Z, Foo SY, Ma Y et al.: HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α. Nature 451, 1008-1012 (2008).
120. Aragones J, Schneider M, Van Geyte K et al.: Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat. Genet. 40, 170-180 (2008).
121. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC: HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 3, 187-197 (2006).
122. Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74, 1124-1136 (1986).
123. Eckle T, Kohler D, Lehmann R, El Kasmi K, Eltzschig HK: Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 118, 166-175 (2008).
124. Jay SM, Shepherd BR, Bertram JP, Pober JS, Saltzman WM: Engineering of multifunctional gels integrating highly efficient growth factor delivery with endothelial cell transplantation. FASEB J. 22, 2949-2956 (2008).
125. Losordo DW, Schatz RA, White CJ et al.: Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation 115, 3165-3172 (2007).
126. Wollert KC, Meyer GP, Lotz J et al.: Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364, 141-148 (2004).
127. Kawamoto A, Tkebuchava T, Yamaguchi J et al.: Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation 107, 461-468 (2003).
128. Lunde K, Solheim S, Aakhus S et al.: Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N. Engl. J. Med. 355, 1199-1209 (2006).
129. Schachinger V, Erbs S, Elsasser A et al.: Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 355, 1210-1221 (2006).
130. Pittenger MF, Martin BJ: Mesenchymal stem cells and their potential as cardiac therapeutics. Circ. Res. 95, 9-20 (2004).
131. Janssens S, Dubois C, Bogaert J et al.: Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 367, 113-121 (2006).
132. Ellis SG, Penn MS, Bolwell B et al.: Granulocyte colony stimulating factor in patients with large acute myocardial infarction: results of a pilot dose-escalation randomized trial. Am. Heart. J. 152, 1051 e9-e14 (2006).
133. Kang HJ, Kim HS, Zhang SY et al.: Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 363, 751-756 (2004).
134. Zohlnhofer D, Ott I, Mehilli J et al.: Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 295, 1003-1010 (2006).